Biovitrum and GlaxoSmithKline to focus efforts on developing highly selective 5-HT2c receptor agonists.

(From Hugin)

Stockholm, May 22, 2003. Biovitrum AB today announced that Biovitrum and GlaxoSmithKline have jointly decided to focus their efforts on the development of highly selective 5-HT2c receptor agonist compounds for the treatment of obesity and other medical disorders. "We have identified other substances in Biovitrum's collection of compounds that show a distinctly higher receptor selectivity", says Ken Batchelor, Metabolic and Viral Center of Excellence for Drug Discovery SVP at GSK. Recommendations from an expert panel of international obesity experts have highlighted selectivity as the key component of an optimal profile for this class of compounds. Recent …